Vistakon Pharmaceuticals

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Vistakon Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 13 completed later-stage tilt top decile by trial count

Vistakon Pharmaceuticals: 13 sponsored US clinical trials, none currently recruiting.

Vistakon Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 10 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, with 1 trials.

Top-decile sponsor footprint

Vistakon Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

13 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

How the Vistakon Pharmaceuticals archive is shaped

13 indexed studies, none listed as recruiting (0% open); 13 completed (100%).

Phase mix: 10 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Vistakon Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Vistakon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share Vistakon PharmaceuticalsAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
Vistakon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vistakon Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Vistakon Pharmaceuticals page

13 registered trials is a research-attention snapshot, not an endorsement of Vistakon Pharmaceuticals or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Vistakon Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.